financetom
Business
financetom
/
Business
/
SBI ex-chairman Rajnish Kumar joins online lender Indifi's board as advisor
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SBI ex-chairman Rajnish Kumar joins online lender Indifi's board as advisor
Apr 28, 2022 10:16 AM

Online lending platform Indifi Technologies on Thursday announced the appointment of SBI's former chairman Rajnish Kumar as an advisor. Kumar is also chairman of the Bharatpe board.

Share Market Live

NSE

In his capacity as an advisor, Kumar will engage with the management on the company's growth strategy and provide guidance in the financial services sector, online lender Indifi said in a statement. Kumar has had a long and illustrious career in banking and finance. He currently sits on the boards of HSBC Asia Pacific, L&T Infotech, Hero MotoCorp and BharatPe.

The MSME sector and their credit gap has been a serious problem for India. The headway that Indifi is making in this regard is important and impressive. Their ecosystem-based approach to lending has leveraged the opportune intersection of digital platforms used by MSMEs and advancement in data and tech, he said.

"I look forward to working with the Indifi team and unlocking future growth opportunities and creating value for all the stakeholders in the company," Kumar was quoted as having said in the statement. Kumar's stint with the State Bank of India (SBI) spanned 40 years till his retirement as the chairman in October 2020. He has also served as the managing director of the National Banking Group.

"We are delighted to have Mr Kumar join us on the advisory board. He is widely regarded as a torchbearer of digital India. This, coupled with his experience and knowledge of the banking and financial services industry, will be truly invaluable to the Indifi's ambitions to spread credit inclusion amongst Indian MSMEs," said Alok Mittal, CEO and Co-Founder of Indifi Technologies.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canacol Energy Says Concerns Over its Ability to Pay Debts
Canacol Energy Says Concerns Over its Ability to Pay Debts "Completely False"
Mar 26, 2024
05:02 PM EDT, 03/26/2024 (MT Newswires) -- Canacol Energy ( CNNEF ) on Tuesday said unspecified speculation over whether the company could meet its debt obligations is completely false. The Colombian oil and gas producer said it is in compliance with all covenants on its debt, though the company suspended its dividend last month to shore up its balance sheet...
Chemours to report Q4 results on March 27
Chemours to report Q4 results on March 27
Mar 26, 2024
March 26 (Reuters) - Chemours ( CC ) said on Tuesday it would report fourth-quarter earnings on March 27 after the chemical company had previously delayed reporting results twice last month. (Reporting by Kabir Dweit in Bengaluru) ...
Green Thumb Industries Insider Sold Shares Worth $298,536, According to a Recent SEC Filing
Green Thumb Industries Insider Sold Shares Worth $298,536, According to a Recent SEC Filing
Mar 26, 2024
05:06 PM EDT, 03/26/2024 (MT Newswires) -- Anthony Georgiadis, Director, President, on March 22, 2024, sold 22,196 shares in Green Thumb Industries ( GTBIF ) for $298,536. Following the Form 4 filing with the SEC, Georgiadis has control over a total of 243,154 shares of the company, with 220,220 shares held directly and 22,934 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1795139/000141588924009136/xslF345X03/form4-03262024_090342.xml ...
US FDA approves Merck's blood pressure therapy
US FDA approves Merck's blood pressure therapy
Mar 26, 2024
March 26 (Reuters) - The U.S. FDA on Tuesday approved Merck's ( MRK ) treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's portfolio. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved